Meet and ask questions to InDex Pharmaceuticals CEO Peter Zerhouni and CMO Dr. Thomas Knittel, when they do a deep dive into the phase lll study design `CONCLUDE´ with cobitolimod in moderate to severe left-sided ulcerative colitis.

InDex Pharmaceuticals is a pharmaceutical development company focusing on immunological diseases, where there is a high unmet medical need for new treatment options. The company’s lead asset is the drug candidate cobitolimod, which is in late-stage clinical development for the treatment of moderate to severe ulcerative colitis – a debilitating, chronic inflammation of the large intestine. InDex Pharmaceuticals has also developed a platform of patent-protected discovery stage substances, so called DNA-based Immuno Modulatory Sequences (DIMS), with the potential to be used in the treatment of various immunological diseases.

InDex Pharmaceutical is based in Stockholm, Sweden.

*Disclaimer: HC Andersen Capital receives payment from the company for a Digital IR / Corporate Visibility subscription agreement. The content does not make recommendations to buy, sell or hold. HC Andersen Capital is an information platform that connects investors and listed companies.